Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38


A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice.

Das K, Eisel D, Vormehr M, Müller-Decker K, Hommertgen A, Jäger D, Zörnig I, Feuerer M, Kopp-Schneider A, Osen W, Eichmüller SB.

BMC Cancer. 2019 Sep 13;19(1):914. doi: 10.1186/s12885-019-6102-6.


Cognate Interaction With CD4+ T Cells Instructs Tumor-Associated Macrophages to Acquire M1-Like Phenotype.

Eisel D, Das K, Dickes E, König R, Osen W, Eichmüller SB.

Front Immunol. 2019 Feb 22;10:219. doi: 10.3389/fimmu.2019.00219. eCollection 2019.


Correction: Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system.

Das K, Eisel D, Lenkl C, Goyal A, Diederichs S, Dickes E, Osen W, Eichmüller SB.

PLoS One. 2018 Dec 19;13(12):e0209719. doi: 10.1371/journal.pone.0209719. eCollection 2018.


MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion.

Ast V, Kordaß T, Oswald M, Kolte A, Eisel D, Osen W, Eichmüller SB, Berndt A, König R.

Oncotarget. 2018 Oct 30;9(85):35559-35580. doi: 10.18632/oncotarget.26263. eCollection 2018 Oct 30.


miR-193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion in vitro.

Kordaß T, Weber CEM, Eisel D, Pane AA, Osen W, Eichmüller SB.

Oncotarget. 2018 Aug 21;9(65):32507-32522. doi: 10.18632/oncotarget.25986. eCollection 2018 Aug 21.


Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.

Kordaß T, Osen W, Eichmüller SB.

Front Immunol. 2018 Apr 18;9:813. doi: 10.3389/fimmu.2018.00813. eCollection 2018. Review.


Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.

Eichmüller SB, Osen W, Mandelboim O, Seliger B.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx034. Review.


Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system.

Das K, Eisel D, Lenkl C, Goyal A, Diederichs S, Dickes E, Osen W, Eichmüller SB.

PLoS One. 2017 Mar 16;12(3):e0174077. doi: 10.1371/journal.pone.0174077. eCollection 2017. Erratum in: PLoS One. 2018 Dec 19;13(12):e0209719.


miR-339-3p Is a Tumor Suppressor in Melanoma.

Weber CE, Luo C, Hotz-Wagenblatt A, Gardyan A, Kordaß T, Holland-Letz T, Osen W, Eichmüller SB.

Cancer Res. 2016 Jun 15;76(12):3562-71. doi: 10.1158/0008-5472.CAN-15-2932. Epub 2016 Apr 15.


Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy.

Lei J, Osen W, Gardyan A, Hotz-Wagenblatt A, Wei G, Gissmann L, Eichmüller S, Löchelt M.

PLoS One. 2015 Sep 23;10(9):e0138458. doi: 10.1371/journal.pone.0138458. eCollection 2015.


Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.

Gardyan A, Osen W, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, Eichmüller SB.

Int J Cancer. 2015 Jun 1;136(11):2588-97. doi: 10.1002/ijc.29322. Epub 2014 Nov 26.


The role of microRNAs in melanoma.

Luo C, Weber CE, Osen W, Bosserhoff AK, Eichmüller SB.

Eur J Cell Biol. 2014 Jan-Feb;93(1-2):11-22. doi: 10.1016/j.ejcb.2014.02.001. Epub 2014 Feb 11. Review.


T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma.

Abschuetz O, Osen W, Frank K, Kato M, Schadendorf D, Umansky V.

Cancers (Basel). 2012 Apr 26;4(2):490-503. doi: 10.3390/cancers4020490.


Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, Umansky V.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17111-6. doi: 10.1073/pnas.1108121108. Epub 2011 Oct 3.


Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.

Osen W, Soltek S, Song M, Leuchs B, Steitz J, Tüting T, Eichmüller SB, Nguyen XD, Schadendorf D, Paschen A.

PLoS One. 2010 Nov 30;5(11):e14137. doi: 10.1371/journal.pone.0014137.


Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.

Kimpfler S, Sevko A, Ring S, Falk C, Osen W, Frank K, Kato M, Mahnke K, Schadendorf D, Umansky V.

J Immunol. 2009 Nov 15;183(10):6330-7. doi: 10.4049/jimmunol.0900609. Epub 2009 Oct 19.


Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma.

Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V.

Clin Cancer Res. 2009 Jul 1;15(13):4382-90. doi: 10.1158/1078-0432.CCR-09-0399. Epub 2009 Jun 23.


Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors.

Umansky V, Abschuetz O, Osen W, Ramacher M, Zhao F, Kato M, Schadendorf D.

Cancer Res. 2008 Nov 15;68(22):9451-8. doi: 10.1158/0008-5472.CAN-08-1464.


Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.

Samorski R, Gissmann L, Osen W.

Immunol Lett. 2006 Sep 15;107(1):41-9. Epub 2006 Aug 4.


Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity.

Strauss G, Osen W, Knape I, Jacobsen EM, Müller SM, Debatin KM.

Cell Death Differ. 2007 Mar;14(3):480-8. Epub 2006 Aug 11.


Identification of a cross-reactive HLA-DRB1*0301-restricted CD4 T cell response directed against cholesterol-binding cytolysins from two different pathogens.

Paschen A, Song M, Schenk S, Janda J, Nguyen XD, Osen W, Schadendorf D, Geginat G.

Microbes Infect. 2006 Jul;8(8):2034-43. Epub 2006 May 30.


An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.

Ohlschläger P, Pes M, Osen W, Dürst M, Schneider A, Gissmann L, Kaufmann AM.

Vaccine. 2006 Apr 5;24(15):2880-93. Epub 2006 Jan 19.


Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice.

Paschen A, Song M, Osen W, Nguyen XD, Mueller-Berghaus J, Fink D, Daniel N, Donzeau M, Nagel W, Kropshofer H, Schadendorf D.

Clin Cancer Res. 2005 Jul 15;11(14):5241-7.


Melanoma patients respond to a new HLA-A*01-presented antigenic ligand derived from a multi-epitope region of melanoma antigen TRP-2.

Paschen A, Jing W, Drexler I, Klemm M, Song M, Müller-Berghaus J, Nguyen XD, Osen W, Stevanovic S, Sutter G, Schadendorf D.

Int J Cancer. 2005 Oct 10;116(6):944-8.


Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice.

Steinberg T, Ohlschläger P, Sehr P, Osen W, Gissmann L.

Vaccine. 2005 Jan 19;23(9):1149-57.


Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Müller M, Pawlita M, Schäfer K, Sehr P, Staib C, Sutter G, Gissmann L.

J Virol. 2003 Apr;77(8):4635-45.


T cell response to human papillomavirus 16 E7 in mice: comparison of Cr release assay, intracellular IFN-gamma production, ELISPOT and tetramer staining.

Michel N, Ohlschläger P, Osen W, Freyschmidt EJ, Guthöhrlein H, Kaufmann AM, Müller M, Gissmann L.

Intervirology. 2002;45(4-6):290-9.


Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination.

Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Müller M.

Virology. 2002 Mar 1;294(1):47-59.


Therapeutic vaccines for human papillomaviruses.

Gissmann L, Osen W, Müller M, Jochmus I.

Intervirology. 2001;44(2-3):167-75. Review.


A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity.

Osen W, Peiler T, Ohlschläger P, Caldeira S, Faath S, Michel N, Müller M, Tommasino M, Jochmus I, Gissmann L.

Vaccine. 2001 Jul 20;19(30):4276-86.


Immunization against human papillomavirus infection and associated neoplasia.

Osen W, Jochmus I, Müller M, Gissmann L.

J Clin Virol. 2000 Oct;19(1-2):75-8.


E7-specific cytotoxic T cell tolerance in HPV-transgenic mice.

Borchers A, Braspenning J, Meijer J, Osen W, Gissmann L, Jochmus I.

Arch Virol. 1999;144(8):1539-56.


Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection.

Schäfer K, Müller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I.

Int J Cancer. 1999 Jun 11;81(6):881-8.


Alloreactivity as a source of high avidity peptide-specific human CTL.

Münz C, Obst R, Osen W, Stevanović S, Rammensee HG.

J Immunol. 1999 Jan 1;162(1):25-34.


Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses.

Speidel K, Osen W, Faath S, Hilgert I, Obst R, Braspenning J, Momburg F, Hämmerling GJ, Rammensee HG.

Eur J Immunol. 1997 Sep;27(9):2391-9.


Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.

Jochmus I, Osen W, Altmann A, Buck G, Hofmann B, Schneider A, Gissmann L, Rammensee HG.

J Gen Virol. 1997 Jul;78 ( Pt 7):1689-95.


Human papillomavirus type 16 (HPV 16) E7 and major histocompatibility complex (MHC) class I and II expression in human keratinocytes in culture.

Hoos A, D'Incan C, Gissmann L, Altmann A, Momburg F, Nindl I, Osen W, Schönning BH, Jochmus I.

Arch Virol. 1996;141(3-4):449-58.


Supplemental Content

Support Center